Clairvo Technologies, Inc.

Name

Clairvo Technologies, Inc.

Legal name

Clairvo Technologies, Inc.

Website

https://clairvotech.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

AI Medical Imaging Software

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD)

akta.pro secondary industry

Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

• Medical imaging AI
• Diagnostic support software
• Medical device distribution
• Healthcare AI solutions
• Radiology software

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Software Sales: Clairvo generates revenue through the sale and distribution of AI-powered medical imaging diagnostic support software in the Japanese market. The company imports medical devices and healthcare products from overseas manufacturers and sells them to Japanese medical institutions. Revenue includes both one-time licensing fees for device certification and ongoing distribution services covering pharmaceutical applications, physical distribution, and sales support.
2. Regulatory and Commercialization Support Services: The company provides one-stop support for overseas manufacturers seeking regulatory approval (pharmaceutical applications) in Japan, including coordination with opinion leaders, construction of distribution networks, and marketing support for sales and distribution.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Clairvo Technologies imports, certifies, and distributes AI-powered medical imaging diagnostic support software and devices from international manufacturers to Japanese medical institutions. The company provides one-stop support covering pharmaceutical regulatory approval, import/export logistics, opinion leader liaison, and construction of distribution networks. Its portfolio includes cardiac CT, chest X-ray, brain MRI, chest CT, retinal imaging, and DICOM standardization AI products, supplemented by handheld fundus camera hardware.

Product overview

Clairvo Technologies, Inc. is a medical device distributor specializing in AI-powered medical imaging diagnostic support products for the Japanese market. The portfolio comprises a mix of certified medical devices and products in regulatory approval stages. Core certified products include Careverse CoronaryDoc (cardiac CT analysis), Clairvo CXR-AI (chest X-ray AI), RyanScope/JulieEye (fundus imaging), VIDA Insights (chest CT), and Neurophet AQUA (brain MRI). Supporting products include ENSIGHT for DICOM standardization, CognICA for cognitive assessment, and several products under development/partnership including V5med chest CT, Yizhun mammography AI, and Shukun cardiac products (CTA and CT-FFR). The company provides comprehensive support from regulatory approval to distribution and sales for international manufacturers.

Differentiator

Problem solved

Functional benefit

Products and services

• Careverse CoronaryDoc Cardiac CT image analysis software that uses deep learning to extract myocardium, blood vessels, stents, and plaques from coronary CT scan data. Creates 3D images, CPR images, and structured reports in approximately 3 minutes without manual intervention, intended for cardiologists and radiology departments performing routine coronary CT examinations.
• Careverse CoronaryDoc Plaque Analysis Option Optional add-on feature for Careverse CoronaryDoc that provides detailed plaque characterization, including calcified, non-calcified, and mixed plaque analysis with CT value range distribution, volume information, histogram display, and structured reporting. Supports CPR and cross-sectional image display for cardiology diagnostic workflows.
• Clairvo CXR-AI AI-assisted chest X-ray image diagnostic support software that detects nodules, masses, and infiltrative shadows to prevent oversights and improve physician sensitivity during diagnostic reading. Targets radiologists and primary care physicians with sensitivity of approximately 83% for nodules/masses and 80% for infiltrative shadows.
• RyanScope Lightweight handheld fundus camera with automatic shooting function for portable, non-mydriatic retinal photography. Compact design prevents camera shake and enables examinations in examination rooms and bedside settings, intended for ophthalmologists, primary care physicians, and home medical care services.
• JulieEye Image analysis software applying deep learning to detect white spots, bleeding, and other symptoms from retinal photographs. Recommends follow-up or specialist examinations based on analysis results, intended for early detection of diabetic retinopathy and other eye diseases in primary care and ophthalmology settings.
• ENSIGHT (ENDEX & ENCOG) Medical image organization and anonymization system utilizing AI. ENDEX organizes and standardizes DICOM tag information into unified terminology, while ENCOG anonymizes personal information in medical images. Together they facilitate medical collaboration, image database construction, and image search for hospitals and research institutions.
• VIDA Insights Chest CT imaging analytics software that quantifies air content and low/high absorption areas in each lung lobe using proprietary technology to provide visually clear information about the entire lung. Certified as a medical device in the US, EU, Canada, and Australia, intended for radiologists and pulmonologists.
• Neurophet AQUA MR device workstation program using deep learning to automatically analyze brain region structures from MR images. Quantifies brain atrophy and white matter high signal areas observed in neurodegenerative diseases across 35 measurement locations, intended for radiologists and neurologists.
• CognICA Self-check tool for cognitive functions utilizing AI. Through categorization of momentarily displayed natural images, it provides a visual classification test that checks accuracy and reaction speed to assess brain function affected before memory impairment onset. Intended for cognitive screening in clinical and research settings.

Quantifiable outcome

• Cardiac CT image processing completed in approximately 3 minutes without manual intervention
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability18 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered flagship and core.

• Shukun Technology Co., Ltd. (数坤科技社)flagshipStrategic or Co-development Partner · 7 April 2025Comprehensive strategic partnership agreement for the Japanese market, building on the March 2024 exclusive business alliance. Aims to establish a framework for continuous and effective introduction of Shukun's full medical imaging AI product portfolio covering heart, brain, chest, abdomen, and MSK disease areas through their Digital Body AI Platform. October 2024 marked the launch of Careverse CoronaryDoc cardiac CT software in Japan.
• Elpixcel Inc. (エルピクセル株式会社)flagshipChannel Partner/ Reseller/ Distributor · 3 June 2024Sales partnership agreement for mutual product distribution. Elpixcel sells Clairvo's CoronaryDoc through its EIRL AI Partner Program, while Clairvo leverages its network to expand sales of Elpixcel's EIRL series. June 2025 announcement confirmed Elpixcel's sale of CoronaryDoc through the EIRL AI Partner Program.
• V5med Inc.coreStrategic or Co-development Partner · 17 April 2024Exclusive business alliance agreement for chest CT imaging diagnostic support software that assists in the detection of nodules from chest CT images. V5med's product has obtained TFDA Class II certification in Taiwan and the companies aim to obtain Japanese regulatory approval.
• Zhejiang Yizhun Medical AI Technology Co., Ltd. (医准智能社)coreStrategic or Co-development Partner · 25 January 2024Exclusive business alliance agreement for mammography X-ray imaging software that assists in the detection of mammary tumors. The product has obtained NMPA Class III certification in China and the companies aim to obtain PMDA approval in Japan.
• Enlitic, Inc.coreStrategic or Co-development Partner · 13 March 2023Exclusive sales agreement in Japan for Curie|ENDEX and Curie|ENCOG, AI-based systems for organizing, standardizing, and anonymizing medical images. Products are non-medical devices. Marubeni (parent at the time) holds exclusive sales rights for APAC markets.
• Medimaging Integrated Solution Inc. (MiiS社)coreChannel Partner/ Reseller/ Distributor · 10 February 2023Exclusive sales agreement in Japan for RyanScope handheld fundus camera and JulieEye image analysis software. Both products obtained managed medical device manufacturing and sales certification in Japan under the Pharmaceuticals and Medical Devices Act.
• NEUROPHET Inc.coreStrategic or Co-development Partner · 1 October 2022Exclusive business alliance contract for Neurophet AQUA, an MR device workstation program using deep learning to automatically analyze brain region structures from MR images for neurodegenerative disease diagnosis support. Contract established through SEOIL E&M Co., Ltd. as intermediary.
• VIDA Diagnostics, Inc.coreChannel Partner/ Reseller/ Distributor · 13 April 2022First product certified under Pharmaceuticals and Medical Devices Act for Clairvo. VIDA Insights image analytics software assists in interpretation of chest CT images by quantifying air content and low/high absorption areas in each lung lobe. Certified as medical device in US, EU, Canada, and Australia.
• TAUNS Laboratories, Inc. (株式会社タウンズ)flagshipOthersParent company (100% shareholder) as of December 23, 2025, following transfer of shares from Marubeni Corporation. Tauns is a major manufacturer of rapid diagnostic test kits for infectious diseases in Japan. The combination of Tauns' diagnostic testing foundation and Clairvo's AI/digital health expertise forms the basis for the group's healthcare strategy.

Scale indicators5 records

Recent moves7 records

Expansion highlights7 records

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/%E3%82%AF%E3%83%AC%E3%82%A2%E3%83%9C%E3%83%BB%E3%83%86%E3%82%AF%E3%83%8E%E3%83%AD%E3%82%B8%E3%83%BC%E3%82%BA%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clairvo Technologies, Inc.